Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin57.2%+3.2pp55.4%+0.3pp54.5%+0.5pp53.9%-0.3pp53.9%-0.5pp
Operating margin-70.1%+7.8pp-71.5%-2.0pp-77.4%+8.9pp-80.1%+35.1pp-78%+87.8pp
Net margin-60.3%+41.4pp-73%+11.1pp-87.9%+12.1pp-94%+50.1pp-101.6%+106pp
Returns
Return on equity-22.7%
Return on invested capital-29.4%
Efficiency
Asset turnover0.3×0.4×-0.1×
Liquidity
Current ratio10.7×-5.2×8.7×+2.4×10.6×14.7×15.9×
Leverage
Debt-to-equity0.0×
Per Share
Book value per share$6.10-40.2%$7.10+118%$6.76+120%$6.95+119%$10.22+129%
Valuation
Market capitalization$708.98M-8.6%$1.34B$863.75M$681.56M
Price / sales6.4×13.4×9.8×8.7×
Price / book2.6×4.7×2.9×2.3×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Beta Bionics, Inc. Common Stock's profit margins?
Beta Bionics, Inc. Common Stock (BBNX) runs a 57.2% gross margin and a -70.1% operating margin, with a -60.3% net margin.
Where do Beta Bionics, Inc. Common Stock's ratios come from?
Every ratio is computed from Beta Bionics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.